Claims
- 1. A cultured somatic animal cell that has a normal karyotype, and, when induced in vitro, develops into an embryoid body.
- 2. A cultured somatic animal cell that has a normal karyotype, and, when introduced into a SCID mouse, develops into a teratoma.
- 3. The cell of claim 2, when induced in vitro, develops into an embryoid body.
- 4. The cell of claim 3 is a mammalian cell.
- 5. The cell of claim 4 is a human cell.
- 6. The cell of claim 5 is stage-specific embryonic antigen-1 negative.
- 7. The cell of claim 4 is stage-specific embryonic antigen-1 negative.
- 8. The cell of claim 3 is stage-specific embryonic antigen-1 negative.
- 9. A method of producing pluripotent animal cells, the method comprising:
isolating somatic cells from a tissue of an animal; culturing the isolated cells under a starving condition; and identifying and enriching pluripotent cells among the cultured cells, wherein the pluripotent cells, when introduced in a SCID mouse, develop into a teratoma.
- 10. The method of claim 9, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 11. The method of claim 9, wherein the animal is a mammal.
- 12. The method of claim 11, wherein the mammal is a human.
- 13. The method of claim 12, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 14. The method of claim 12, wherein the tissue is umbilical cord blood, bone marrow, amniotic fluid, adipose tissue, placenta, or peripheral blood.
- 15. The method of claim 14, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 16. The method of claim 14, wherein the tissue is umbilical cord blood, bone marrow, or amniotic fluid.
- 17. The method of claim 16, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 18. The method of claim 16, wherein the culturing step is performed by placing cells in a medium containing 0.5% to 2% serum for 5 to 10 days or in a medium containing 10% to 20% serum for 7 to 21 days 0 without changing the medium.
- 19. The method of claim 18, wherein the culturing step is performed by placing cells in a medium containing 0.5% serum for 5-7 days or in a medium containing 20% serum for 2 weeks without changing the medium.
- 20. The method of claim 19, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 21. The method of claim 14, wherein the culturing step is performed by placing cells in a medium containing 0.5% to 2% serum for 5 to 10 days or in a medium containing 10% to 20% serum for 7 to 21 days without changing the medium.
- 22. The method of claim 21, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 23. The method of claim 21, wherein the culturing step is performed by placing cells in a medium containing 0.5% serum for 5-7 days or in a medium containing 20% serum for 2 weeks without changing the medium.
- 24. The method of claim 23, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 25. The method of claim 12, wherein the culturing step is performed by placing cells in a medium containing 0.5% to 2% serum for 5 to 10 days or in a medium containing 10% to 20% serum for 7 to 21 days without changing the medium.
- 26. The method of claim 25, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 27. The method of claim 11, wherein the tissue is umbilical cord blood, bone marrow, amniotic fluid, adipose tissue, placenta, or peripheral blood.
- 28. The method of claim 11, wherein the culturing step is performed by placing cells in a medium containing 0.5% to 2% serum for 5 to 10 days or in a medium containing 10% to 20% serum for 7 to 21 days without changing the medium.
- 29. The method of claim 9, wherein the tissue is umbilical cord blood, bone marrow, amniotic fluid, adipose tissue, placenta, or peripheral blood.
- 30. The method of claim 29, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 31. The method of claim 29, wherein the tissue is umbilical cord blood, bone marrow, or amniotic fluid.
- 32. The method of claim 31, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
- 33. The method of claim 31, wherein the culturing step is performed by placing cells in a medium containing 0.5% to 2% serum for 5 to 10 days or in a medium containing 10% to 20% serum for 7 to 21 days without changing the medium.
- 34. The method of claim 29, wherein the culturing step is performed by placing cells in a medium containing 0.5% to 2% serum for 5 to 10 days or in a medium containing 10% to 20% serum for 7 to 21 days without changing the medium.
- 35. The method of claim 9, wherein the culturing step is performed by placing cells in a medium containing 0.5% to 2% serum for 5 to 10 days or in a medium containing 10% to 20% serum for 7 to 21 days without changing the medium.
- 36. The method of claim 35, wherein the pluripotent cells are stage-specific embryonic antigen-1 negative.
RELATED APPLICATION
[0001] This application claims priority to U.S. Provisional Application Serial No. 60/398,883, filed Jul. 26, 2002, the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60398883 |
Jul 2002 |
US |